Instrument Inactif

Autres langues ContraVir Pharmaceuticals Inc Nasdaq

Actions

US21234W1036

Recherche biotechnologique et médicale

Autres langues

03/09	Hepion Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Gravitas Capital Partners
25/08	Hepion Pharmaceuticals, Inc. announced that it expects to receive $0.4 million in funding
20/08	Hepion Pharmaceuticals, Inc. Announces Appointment of James Liddy to Director, Effective August 19, 2026
13/08	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Hepion Pharmaceuticals, Inc. announced that it has received $3.055 million in funding
31/07	Hepion Pharmaceuticals, Inc. announced that it expects to receive $3.055 million in funding
02/07	Hepion Pharmaceuticals, Inc. Approves Board Appointments, Effective July 1, 2026
14/05	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
21/04	Hepion Pharmaceuticals, Inc. announced that it has received $0.7 million in funding
14/04	Hepion Pharmaceuticals, Inc. Announces Resignation of Kaouthar Lbiati as A Director on April 13, 2026
18/03	Hepion Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective March 16, 2026
18/03	Hepion Pharmaceuticals, Inc. Announces Board Appointments
12/03	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
12/03	Hepion Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
03/03	Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
15/01	Hepion Pharmaceuticals, Inc. Approves Employment Agreement of Kaouthar Lbiati as Chief Executive Officer, Effective as of January 8, 2026
12/11	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/08/25	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
30/06/25	Hepion Pharmaceuticals, Inc. Announces Resignation of John Brancaccio as Director, Effective June 30, 2025
30/06/25	Hepion Pharmaceuticals, Inc. Announces Resignation of John Brancaccio as Chief Financial Officer, Effective June 30, 2025
25/06/25	Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
16/06/25	Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
16/06/25	Hepion Pharmaceuticals, Inc Announces CEO Changes
19/05/25	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
13/05/25	Hepion Pharmaceuticals, Inc.(OTCPK:HEPA) dropped from S&P TMI Index